Bio-Path Doses Patient in Amended Phase 2 Prexigebersen Trial

Biotech Investing

Bio-Path Holdings (NASDAQ:BPTH) has announced patient dosing in its amended Phase 2 trial of prexigebersen to treat acute myeloid leukemia (AML). As quoted in the press release: The key change in the amended Phase 2 study is the inclusion of patients with high risk myelodysplastic syndrome (MDS) and refractory/relapsed AML patients. The restructured Phase 2 …

Bio-Path Holdings (NASDAQ:BPTH) has announced patient dosing in its amended Phase 2 trial of prexigebersen to treat acute myeloid leukemia (AML).

As quoted in the press release:

The key change in the amended Phase 2 study is the inclusion of patients with high risk myelodysplastic syndrome (MDS) and refractory/relapsed AML patients. The restructured Phase 2 clinical trial has two cohorts of patients. The first being untreated AML patients as existed in the pre-amended trial but with the addition of high risk MDS patients, and a second cohort comprised of refractory/relapsed AML patients and high risk MDS patients.

The amended Phase 2 study will continue evaluating the safety of prexigebersen in combination with decitabine in both cohorts of patients at a dose of 60 mg/m2 in combination with decitabine. The study will include a total of six evaluable patients for a safety assessment of prexigebersen and decitabine. To date, the Company has enrolled five evaluable patients: three untreated AML patients in who received therapy prior to amending the trial, and two patients who are now being treated under the amended Phase 2 trial. Assuming a successful completion of this safety assessment, the study will then modify testing of both cohorts of patients to add venetoclax to the prexigebersen/decitabine combination treatment.

After a six-patient safety assessment of the prexigebersen/decitabine/venetoclax combination, the Company intends to commence the efficacy segment of this trial. It is anticipated that each cohort will include an interim assessment of 19 evaluable patients that would assess whether the treatment efficacy of the combination of prexigebersen/decitabine/ venetoclax exceeds the efficacy of current standard-of-care therapy with statistical significance. Upon such favorable data, Bio-Path would petition the U.S. Food and Drug Administration (FDA) for accelerated approval. The efficacy segment of the trial is expected to be conducted at up to ten clinical sites in the United States. Moving forward, the Company intends to evaluate potential clinical sites in Europe with an emphasis on patient accruals.

Click here to read the full press release.

The Conversation (0)
×